title: Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer.
abstract: BACKGROUND
  The receptor for advanced glycation endproducts (RAGE) and microvascular status both play a critical role in cancer progression. However, the crosstalk between RAGE and microvascular formation in endometrial cancer remains largely unknown.
  
  
  METHODS
  RAGE expression and microvessel density were examined in 20 cases of normal endometrial tissue, 37 cases of well-differentiated endometrial cancer tissue, and 35 cases of poorly-differentiated endometrial cancer tissue. Regression analysis was used to examine the relationship between RAGE and microvessel density. The knockdown of RAGE was achieved using a small interfering RNA in HEC-1A endometrial cancer cells. A xenografted tumour model was used to evaluate RAGE-mediated microvascular formation and proliferation of endometrial cancer cells.
  
  
  RESULTS
  It was shown that (i) RAGE expression gradually increased in normal endometrium, well-differentiated endometrial cancer, and poorly-differentiated endometrial cancer, respectively; (ii) a positive correlation existed between RAGE and microvessel density in human endometrial cancer samples; (iii) RAGE knockdown was effective in decreasing microvessel formation in xenografted tumour models; and (iv) RAGE knockdown can significantly inhibit the proliferation of endometrial cancer cells in vivo.
  
  
  CONCLUSIONS
  These results indicate that RAGE may be a potential trigger in microvascular formation and proliferation in the development of endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. zhenglu1980@yeah.net.|Department of Obstetrics and Gynecology, Central Hospital of Shenyang Medical College, Shenyang, 110024, China. zhenglu1980@yeah.net.
authors.forename: Lu
authors.initials: L
authors.lastname: Zheng
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. leeda@ymail.com.
authors.forename: Da
authors.initials: D
authors.lastname: Li
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, 02115, USA. yzhou22@partners.org.
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Zhou
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. 80719538@qq.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Yang
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. dicheng1987@yeah.net.
authors.forename: Di
authors.initials: D
authors.lastname: Cheng
authors.affiliation: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. maxx_cmu@163.com.
authors.forename: Xiao-Xin
authors.initials: XX
authors.lastname: Ma
mesh_terms: D000368:Aged; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics*; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D055806:Microvessels / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D000067759:Receptor for Advanced Glycation End Products / Q000096:biosynthesis / Q000235:genetics*; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: D000067759:Receptor for Advanced Glycation End Products